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ABSTRACT 
 
Evaluation of mediastinal lymphadenopathy in patients with 
a previous diagnosis of renal cell carcinoma (RCC) is 
critical for the determination of further treatment.  A 
minimally invasive method of cytology sampling of 
mediastinal lymph nodes using endobronchial ultrasound-
guided transbronchial needle aspiration (EBUS-TBNA) has 
emerged as a useful tool in diagnosis. Between January 2010 
and April 2018, we performed 1,744 EBUS-TBNA studies of 
mediastinal and hilar lymph nodes for a variety of clinical 
indications including mediastinal malignancy. Sixteen 
patients (93.7% males, mean age 59.1 years, range 44-81 
years) were diagnosed by cytological and cell block study to 
have metastatic clear cell RCC. Twelve patients had been 
diagnosed with clear cell RCC in the past (mean 39 months, 
range 4 to 89 months) while in four, the tumor was primarily 
diagnosed in the staging phase on the basis of EBUS-TBNA. The 
EBUS features of the mediastinal nodal masses included 
increase of size (mean 2.5 cm, range 1.6-3.8 cm), irregular, 
inhomogeneous, hypervascular, and hyperechoic echotexture. 
EBUS-TBNA is a procedure safe and effective for evaluating 
mediastinal lymphadenopathy in patients with clear cell RCC. 
Immunohistochemistry in the cell block is decisive for proper 
diagnosis. The cytologist plays a key role in the diagnosis 
of metastatic clear cell RCC due to the treatment 
implications that this neoplasm encompasses. 
 
Keywords: Bronchoscopy, Mediastinal lymph node, Renal cell 
carcinoma, Ultrasound-guided cytology  
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1. Introduction 
Renal cell carcinoma (RCC) is the third most common urologic 
neoplasm and accounts for about 5% of adult cancers in men 
and 3% in women [1]. The most common metastatic sites in 
order of frequency are lung, bone, lymph nodes, liver, 
adrenal, and brain [2].   
Patients treated for RCC can subsequently develop one or 
several mediastinal lymphadenopathies. Furthermore, it has 
been demonstrated that RCC may metastasize to mediastinal 
lymph nodes without any abdominal lymph node involvement 
[3,4]. Exceptionally, mediastinal disease can be the initial 
manifestation of RCC [5-7]. Accurate pathological diagnosis 
of such mediastinal lesions is critical for effective 
treatment. Mediastinoscopy and open thoracic surgery are 
standard methods for mediastinal lymph node staging. 
However, they are invasive and costly, require general 
anesthesia, and complications cannot be ignored. Endoscopic 
ultrasonography-guided fine-needle aspiration (EUS-FNA) 
biopsy of mediastinal lymph nodes is a minimally invasive 
modality for tissue sampling of the mediastinum [8]. However, 
in terms of accessibility to some lymph nodes and of the 
amount of tissue that can be obtained, the procedure is 
limited.  
Endobronchial ultrasound-guided transbronchial needle 
aspiration (EBUS-TBNA) cytology is a minimally invasive, 
safe and feasible procedure that can be used for diagnosing 
mediastinal lymphadenopathy [9].  There are reports of 
isolated cases [10,11] or small series [9] in the literature 
using this technique to detect metastatic RCC to the 
mediastinal lymph nodes.                                                                                                                                                                                                                                                                                                                                          
In this study, we investigated the feasibility of EBUS-TBNA 
for evaluating mediastinal lymphadenopathy in clear cell 
RCC. Mediastinal lymph node metastases presented as a 
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recurrence or a primary diagnosis in a series of 16 patients 
diagnosed with clear cell (conventional) RCC.   
2. Materials and methods 
Between January 2010 and April 2018, we performed 1,744 EBUS-
TBNA studies of mediastinal lymph nodes for a variety of 
clinical indications including mediastinal malignancy. In 
this study, EBUS-TBNA was used to assess mediastinal and 
hilar lymph nodes for the presence of metastatic clear cell 
RCC. All the cases were seen in-house. The lymph nodes 
sampled were enlarged (short axis > 1cm) according to 
computed tomography (CT) scans, and they were associated in 
some cases with nodular lesions in the lung. 
Tumor staging was established according to the 7th edition 
of the AJCC Cancer Staging Manual [12]. Nuclear grade in the 
renal surgical specimens was established according to 
Fuhrman et al [13]. 
The determination of the suitability of the patient was made 
based on the location of the suspected nodal metastasis.  
EBUS-TBNA was performed under local anesthesia and midazolam 
and fentanyl sedation as an outpatient procedure, using a 
flexible bronchoscope Olympus BF-UC160F-OL8 (Olympus, Tokyo, 
Japan) and an ultrasound image processor Olympus EUS Exera 
EU-c60 (Olympus, Tokio, Japan). Specimens were obtained with 
a 22-gauge needle. The average number of needle passes from 
each location was 3 (range 1-6).  
An on-site evaluation was performed in all the cases and the 
specimen was deemed adequate. Each case had aspirate smears 
that were stained with Diff-Quick and Papanicolaou method. 
In all the cases we had cell block preparations. Sections of 
the cytoblocks were stained with hematoxylin and eosin. 
Immunopathological study was carried out on formalin-fixed 
4-µm-thick paraffin-embedded tissue sections using the 
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EnVision FLEX Visualization System (Dako, Agilent 
Technologies, SL, Las Rozas, Madrid, Spain). Antibodies used 
in the immunohistochemical study are detailed in Table 1. 
The immunohistochemical reactions were performed using 
appropriate tissue controls. Automatic staining was 
accomplished on a Dako Omnis autostainer (Agilent 
Technologies, SL). Because of limited material and variation 
of the staining panel over the years, not all tumors were 
stained with the same series of antibodies.  
3. Results 
Over the study period (8 years and four months), we analyzed 
the data from 16 patients who underwent EBUS-TBNA with 
cytoblock. The patients underwent EBUS-TBNA because of 
suspected mediastinal metastasis according to CT. Twelve 
patients had been diagnosed with clear cell RCC in the past 
(mean 39 months, range 4 to 89 months) while in four, this 
tumor was primarily diagnosed in the staging phase by means 
of EBUS-TBNA (Table 2). At CT scan these four cases showed 
large, expansile, polylobulated, heterogeneous lesions due 
to internal necrosis and occasional calcifications. The 
peripheral areas were solid with mean density at the pre-
contrast phase and intense contrast uptake at the cortico-
medullary phase (Fig. 1). Perirenal adipose tissue invasion 
or renal sinus invasion was observed in all cases. 
There were 16 (93.7%) male patients and the mean age was 
59.1 years (range 44-81 years). The mean mediastinal lymph 
node size detected with CT and EBUS-TBNA was 2.5 cm (range 
1.6-3.8 cm). Nine (52.6%) cases had solitary metastases in 
the mediastinum in absence of lung metastases. The interval 
to metastases varied from 0 to 89 months with a mean of 29.2 
months.  
CT-scans with contrast enhancement in 16 patients showed 
well-defined, large (Fig. 2A), heterogeneously enhancing 
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solid lesions with irregular central necrosis in the 
mediastinum (Fig. 2B and 2C). Some hyperenhancing lymph nodes 
simulated vascular structures. Reviewing the EUS features of 
the mediastinal nodal masses in these patients revealed that 
they were large (Fig. 2D), irregular, inhomogeneous, 
hypervascular, and mostly hyperechoic. No calcifications 
were seen in any of these lymph nodes. 
Cytological smears showed a lymphoid and hemorrhagic 
background on which there were large, epithelioid cells 
arranged in flat cohesive sheets (Fig. 3A), small clusters 
(Fig. 3B) or scattered as isolated elements. Cellularity was 
low (20%) to moderate (80%). The cells had abundant cytoplasm 
and a centrally or eccentrically located round to slightly 
irregular nucleus. In most cases, these cells exhibited a 
visible or prominent nucleolus. Cytoplasms were translucent, 
vacuolated, or granular eosinophilic. Nuclear grooves or 
foamy cytoplasms were not seen. In some cases, the isolated 
tumor cells resembled macrophages. However, these cells did 
not show anthracotic pigment and presented nuclear atypia. 
Occasionally, the extensions showed groups of cartilaginous 
cells, bronchial glands or ciliated cells of the bronchial 
mucosa. All the patients were found to have cytological 
findings compatible with metastatic clear cell RCC.  
The cell blocks showed fragments of tumor tissue (Fig. 4A). 
The neoplasms were constituted by polygonal cells limited by 
prominent sinusoidal vascular networks. The observed 
architectural patterns were: solid nests (81.2%), alveoli 
(12.5%), and enlarged vascular spaces (6.2%). Cells were 
large and separated from one another by well-defined cell 
borders. These cells often had clear moderate to voluminous 
cytoplasm (Fig. 4B). Others showed fine granular, 
acidophilic cytoplasm. All tumors contain clear cells and a 
variable proportion of cells with eosinophilic cytoplasm 
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(Fig. 4C). Predominance of eosinophilic cells was observed 
in 81% (13/16) of tumors. Nuclei tended to be round to oval, 
and uniform with granular evenly distributed chromatin. 
Depending upon the degree of differentiation nucleoli could 
be sparse, large or prominent and the nuclei markedly 
enlarged with irregular shapes, and pleomorphism. A poorly 
differentiated tumor showing hyperchromatic, pleomorphic 
nuclei and pink eosinophilic cytoplasm can be observed in 
Fig. 4D. The Fuhrman nuclear grades were not assessed in the 
tissue sections of the cytoblocks.  
Immunohistochemical studies revealed reactivity of the tumor 
cells for RCC marker (13/15, 86.7%) (Fig. 5A), cluster of 
differentiation 10 (CD10, 12/14, 85.7%) (Fig. 5B), paired 
box 8 (PAX8, 14/14, 100%) (Fig. 5C), cytokeratin (CK) AE1/AE3 
(15/15, 100%), epithelial membrane antigen (EMA, 15/15, 
100%), carbonic anhydrase IX (CAIX, 12/12, 100%) (Fig. 5D), 
and vimentin (15/15, 100%). There was no reactivity for 
thyroid transcription factor-1 (TTF-1, 0/15, 0%), CK 7 (0/3, 
0%), p63 (0/3, 0%) and p40 (0/3, 0%). 
In the present study, there were no inadequate samples. No 
complications were observed in patients due to the use of 
the EBUS-TBNA procedure. 
4. Discussion 
Clear cell RCC is the most common variant of RCC accounting 
for about 75% of cases. The tumor typically develops during 
adulthood, with the incidence peaking during the sixth and 
seventh decades of life. The neoplasm occurs nearly twice as 
often in men as in women. Metastatic RCC is present in 25-
30% of patients at diagnosis [14]. The tumor metastasizes to 
the lung through a hematogenous route. Metastases to the 
mediastinal lymph nodes are usually associated with lung 
metastases. Metastases to the mediastinal lymph nodes occur 
via a lymphogenous route from pulmonary metastatic lesions 
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including undetected micrometastasis. Other possible 
pathways include a lymphogenous route via the thoracic duct 
(through a retrograde flow) or the inferior pulmonary 
ligament (through the retroperitoneal lymphatics) [15].  
Anyway, RCC rarely shows solitary mediastinal lymph node 
metastases without lung metastases [5-7,15]. 
In patients with mediastinal lesions and a past history of 
RCC, is crucial to distinguish metastatic recurrence from 
other causes of mediastinal lymphadenopathy such as 
tuberculosis, sarcoidosis, or lymphoma.   
Radiologic diagnosis of lymph node involvement is based on 
morphologic criteria, especially increase in size observed 
at CT-scans. It is generally accepted that a normal lymph 
node has a maximum short-axis diameter of 10 mm or less [16]. 
However, about five percent of metastatic lymph nodes for 
RCC are smaller than 10 mm. In these cases the tumor invasion 
is microscopic. On the other hand, lymph nodes larger than 
2 cm are almost always involved by metastases [17]. In 
addition, hypervascularity and inhomogeneous enhancement of 
enlarged lymph nodes should raise suspicion for malignant 
invasion [16]. The overall accuracy of lymph node staging by 
CT in RCC is reported to be between 83% and 89%. False-
negative results caused by microscopic invasion occurs in 4-
5% of cases [17].  
It has been demonstrated that echofeatures alone are not 
reliable in determining the underlying etiology of the 
mediastinal lymphadenopathy [18]. Nevertheless, malignant 
mediastinal lymph nodes tend to be larger than non-malignant 
lymph nodes. Thus, larger lymph nodes in the elderly may 
carry a higher risk of malignancy and should undergo EBUS-
TBNA. 
Determining the primary location of the tumor based only on 
the cytology of metastatic lesions can be difficult in view 
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of the overlap in the morphology of different tumors such as 
carcinomas, melanomas, sarcomas, and lymphomas. Another 
factor is the variable origin of visceral clear-cell tumors 
from kidney, liver, adrenal, ovary, cervix, thyroid, breast, 
lung, alimentary tract, or salivary glands which increases 
the difficulty of identifying the primary site [19]. 
Therefore, EBUS-TBNA with the study of the cytoblock and the 
help of immunohistochemistry is especially useful in the 
evaluation of the mediastinum for suspected metastases. 
According to the International Society of Urologic Pathology 
Consensus Conference, PAX8 is the most useful marker for 
establishing the diagnosis of metastatic RCC, and CAIX is 
characteristically overexpressed in clear cell RCC in a 
membranous pattern [20]. In addition, clear cell RCC commonly 
express vimentin, epithelial markers such as CK AE1/AE3, CAM 
5.2 and EMA, RCC marker and CD10. Vimentin is more intensely 
positive in high-grade tumors. RCC marker exhibits 
cytoplasmic and membranous positivity and its expression 
decreases with increasing grade. However, the fact that other 
tumors can express positivity for vimentin, epithelial 
markers, and CD10 limits their utility in difficult cases 
[20]. The most useful markers in the separation of clear 
cell from chromophobe RCC are CK7, RCC marker, CD10, 
vimentin, and CD117 [21].  
On the other hand, immunohistochemistry is necessary in cases 
of high-grade, poorly differentiated tumors. In this 
context, the differentiation between urothelial carcinoma 
(UC) and clear cell RCC is critical. A panel highly sensitive 
for clear cell RCC includes vimentin, PAX8, CD10, and CAIX. 
The immunohistochemical profile of UC involves positivity 
for p63, CK7, INI-1, high molecular weight CK [22], or 
uroplakin II, GATA3, and p40 [23]. It should be noted that 
UC can be positive for PAX8 and CAIX in 17% and 33% of cases 
respectively [22].  
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Patients with isolated, asynchronous metastases in the 
mediastinal lymph nodes are amenable to a surgical resection. 
This treatment is safe, appears to extend survival, and 
should be considered an important component of treating 
patients with RCC who have asynchronous lymph node metastases 
[15,24,25]. 
Currently, National Comprehensive Cancer Network in the USA 
and European Association of Urology guidelines in Europe, 
emphasize the importance of clear cell histopathology versus 
non-clear cell histopathology as a key therapeutic decision 
point in the setting of stage IV (metastatic/unresectable, 
or metastatic recurrent) RCC [26,27]. Thus, PAX8 plus CAIX 
expression not only establishes a clear cell RCC diagnosis 
but also identifies a therapeutically actionable group for 
tyrosine-kinase inhibitors and/or potent immunotherapies 
that abrogate the PD-1 pathway [28]. Therefore, in this 
setting, the cytologist plays a key role in diagnosis and 
acquires a high degree of responsibility.  
The complication rate for EBUS-TBNA is low and varies from 
1.23% [29] to 1.44% [30]. They include device breakage, 
hemorrhage, pneumothorax, infections (mediastinitis, 
pneumonia, pericarditis, sepsis), and death (large cerebral 
infarction reported in one case) [29,30]. Regarding the 
benefits, EBUS-TBNA can reach multiple nodal stations, 
including the hilar lymph nodes. In addition, advantages 
such as adequacy assessment of the specimen, improved 
diagnostic yield, and reduction of additional procedures 
contribute to improving patient care [31].    
In Conclusion, EBUS-TBNA is a minimally invasive procedure 
safe and feasible for evaluating mediastinal lymphadenopathy 
in patients with clear cell RCC. Immunohistochemistry in the 
cell block is definitive for precise diagnosis. The 
cytologist plays a key role in the diagnosis of metastatic 
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clear cell RCC due to the treatment implications that this 
neoplasm entails. 
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Figure captions 
Fig. 1. Thoraco-abdominal CT scan. Intravenous contrast in 
portal phase. Solid, exophytic, polylobulated mass located 
in the middle renal segment of the left kidney with a large 
hypodense central area of necrotic appearance (case 6). 
Image: (A) axial, (B) coronal, and (C) sagittal. 
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Fig. 2. Radiological findings. (A) Coronal thoracic CT scan. 
The arrow indicates an enlarged infracarinal lymphadenopathy 
(level 7). It is homogeneous, hypodense and rounded (case 
11). (B) Axial thoracic CT image. The arrow points to an 
enlarged right hilar lymph node (10R), with a hypodense 
center suggestive of necrosis and with a polylobulated 
morphology (case 13). (C) Coronal thoracic CT scan. The arrow 
indicates a heterogeneous large lymph node in the most distal 
region of the left hilum (left interlobar, 11L). The 
hypodense internal areas suggest necrosis (case 14). (D) 
Endobronchial ultrasound image of an enlarged subcarinal 
lymphadenopathy (level 7) showing transbronchial needle 
aspiration (case 11).  
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Fig. 3. Cytological smears. (A) Flat cohesive sheet of  cells 
with abundant cytoplasm and a centrally or eccentrically 
located round to oval nucleus. Nucleoli are visible (case 4, 
Papanicolaou stain, x400). (B) Cytological smear showing a 
lymphoid and hematic background on which there is a group of 
large atypical cells with abundant cytoplasm and 
eccentrically located round nucleus (case 7, Diff-Quick 
stain, x400). 
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Fig. 4. Routine hematoxylin-eosin stain of the cell blocks. 
(A) Presence of tissue fragments of carcinoma cells in a 
background of red cells (Case 14, x100). (B) Solid 
architectural pattern of cells showing clear cytoplasm and 
distinct cell membranes (case 16, x400). (C) Tumor rich in 
cells with eosinophilic cytoplasm (case 14, x400). (D) 
Carcinoma cells displaying hyperchromatic and pleomorphic 
nuclei and eosinophilic cytoplasm (case 13, x400).  
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Fig. 5. Immunohistochemistry. Tumor cells show reactivity 
for: (A) renal cell carcinoma marker (case 8, x400), (B) 
CD10 (case 11, x400), (C) PAX8 (case 11, x400), and (D) CAIX 
(case 6, x400).  
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Table 1. Immunohistochemical antibodies used in the study 
Antibody Source Clone Dilution Retrieval 
solution pH 
(Dako) 
Renal cell 
carcinoma 
marker 
Dako SPM314 FLEX RTU Low 
CD10 Dako 56C6 FLEX RTU Low 
PAX8 Dako Polyclonal 1:400 Low 
TTF-1 Dako 8G7G3 FLEX RTU High 
Cytokeratin Dako AE1/AE3 FLEX-RTU High 
Epithelial 
membrane 
antigen 
Dako E29/EP1 FLEX-RTU High 
CAIX Abcam Polyclonal 1:1000 Low 
Vimentin Dako V9 FLEX-RTU High 
Cytokeratin 
7 
Dako OV-TL 12/30 FLEX-RTU High 
p63 Dako DAK-p63 FLEX-RTU High 
P40 Biocare 
Medical 
BC28 1:50 High 
Dako (Agilent Technologies, SL, Las Rozas, Madrid, Spain); 
Abcam, Cambridge, United Kingdom; Biocare Medical, Alcalá de 
Henares, Madrid, Spain  
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Table 2. Clinical details of patients with mediastinal 
metastases caused by clear cell renal cell carcinoma 
Case 
No 
Age at 
metastases(y)/Sex 
Thoracic 
imaging 
Mediastinal 
lymph node 
máximum 
diameter 
(cm) 
Previous 
tumor staging 
Interval 
to 
metastasis 
(months)  
1 50/M Mediastinal 
lymph nodes 
Pulmonary 
nodes  
2.9 pT2aN0M0,g3 16 
2 62/M Mediastinal 
lymph nodes 
Pulmonary 
nodes 
2.5 pT3bN0M0,g2 72 
3 49/F Mediastinal 
lymph nodes 
Pulmonary 
nodes 
2.0 pT2bN2M0,g3 4 
4 69/M Mediastinal 
lymph nodes 
Pulmonary 
nodes 
3.5 pT4N0M1 26 
5 57/M Mediastinal 
lymph nodes 
3.0 pT3bN0M0,g3 47 
6 51/M Mediastinal 
lymph nodes 
1.6 pT3aN0M1,g3 0 
7 74/M Mediastinal 
lymph nodes 
1.7 pT3aN0M0,g4 7 
8 64/M Mediastinal 
lymph nodes 
2.4 T3N0M1 0 
9 81/M Mediastinal 
lymph nodes 
Pulmonary 
nodes 
2.5 pT2aN0M0,g3 89 
10 63/M Mediastinal 
lymph nodes 
3.5 pT2bN0M0,g3 55 
11 44/M Mediastinal 
lymph nodes 
2.3 pT2aN0M0,g3 39 
12 56/M Mediastinal 
lymph nodes 
Pulmonary 
nodules 
3.8 T3N2M1,g4 0 
13 46/M Mediastinal 
lymph nodes 
2.0 pT3aN0M1,g4 0 
14 56/M Mediastinal 
lymph nodes 
2.4 pT1bN0M0,g2 22 
15 59/M Mediastinal 
lymph nodes 
1.7 pT3aN0M0,g2 24 
16 65/M Mediastinal 
lymph node 
Pulmonary 
nodules 
2.0 pT1bpN0pM1,g3 67 
g, Fuhrman grade 
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